194 related articles for article (PubMed ID: 20230905)
1. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Flanagan JM; Howard TA; Mortier N; Avlasevich SL; Smeltzer MP; Wu S; Dertinger SD; Ware RE
Mutat Res; 2010 Apr; 698(1-2):38-42. PubMed ID: 20230905
[TBL] [Abstract][Full Text] [Related]
2. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
4. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
Flanagan JM; Steward S; Howard TA; Mortier NA; Kimble AC; Aygun B; Hankins JS; Neale GA; Ware RE
Br J Haematol; 2012 Apr; 157(2):240-8. PubMed ID: 22360576
[TBL] [Abstract][Full Text] [Related]
5. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
7. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
9. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.
McGann PT; Howard TA; Flanagan JM; Lahti JM; Ware RE
Br J Haematol; 2011 Jul; 154(1):134-40. PubMed ID: 21542824
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease.
Harrod VL; Howard TA; Zimmerman SA; Dertinger SD; Ware RE
Exp Hematol; 2007 Feb; 35(2):179-83. PubMed ID: 17258066
[TBL] [Abstract][Full Text] [Related]
11. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
[TBL] [Abstract][Full Text] [Related]
12. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients.
Torous DK; Avlasevich S; Bemis JC; Howard T; Ware RE; Fung C; Chen Y; Sahsrabudhe D; MacGregor JT; Dertinger SD
Environ Mol Mutagen; 2023 Mar; 64(3):167-175. PubMed ID: 36841969
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
Walker AL; Steward S; Howard TA; Mortier N; Smeltzer M; Wang YD; Ware RE
Blood; 2011 Nov; 118(20):5664-70. PubMed ID: 21921042
[TBL] [Abstract][Full Text] [Related]
15. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
DeBaun MR
Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
[TBL] [Abstract][Full Text] [Related]
19. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
RodrÃguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
20. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
O'branski EE; Ware RE; Prose NS; Kinney TR
J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
